Biological synthesis of pharmaceuticals and biochemicals offers an environmentally friendly alternative to conventional chemical synthesis. These alternative methods require the design of metabolic pathways and the identification of enzymes exhibiting adequate activities. Cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates are natural metabolites which possess beneficial activities for human health, and the search is expanding for novel derivatives that might have enhanced biological activity. For example, biosynthesis in Dianthus caryophyllus is catalyzed by hydroxycinnamoyl/benzoyl-CoA:anthranilate N-hydroxycinnamoyl/ benzoyltransferase (HCBT), which couples hydroxycinnamoyl-CoAs and benzoyl-CoAs to anthranilate. We recently demonstrated the potential of using yeast (Saccharomyces cerevisiae) for the biological production of a few cinnamoyl anthranilates by heterologous co-expression of 4-coumaroyl:CoA ligase from Arabidopsis thaliana (4CL5) and HCBT. Here we report that, by exploiting the substrate flexibility of both 4CL5 and HCBT, we achieved rapid biosynthesis of more than 160 cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates in yeast upon feeding with both natural and non-natural cinnamates, dihydrocinnamates, benzoates, and anthranilates. Our results demonstrate the use of enzyme promiscuity in biological synthesis to achieve high chemical diversity within a defined class of molecules. This work also points to the potential for the combinatorial biosynthesis of diverse and valuable cinnamoylated, dihydrocinnamoylated, and benzoylated products by using the versatile biological enzyme 4CL5 along with characterized cinnamoyl-CoA-and benzoyl-CoA-utilizing transferases.
Introduction
Cinnamoyl and benzoyl anthranilates are bipartite molecules consisting of cinnamate or benzoate moieties amide-linked to anthranilic acids (Fig 1) . The beneficial pharmacological effects of these molecules on human health have been well-documented over the past few years. For example, avenanthramides are natural cinnamoyl anthranilates found in oats and possess antioxidant, anti-inflammatory, and antiproliferative bioactivities [1, 2] . Tranilast ([N-(3',4'-dimethoxycinnamoyl)-anthranilic acid], Fig 1A) is a synthetic cinnamoyl anthranilate marketed in Japan for the treatment of allergic diseases, scleroderma, and hypertrophic scars associated with excessive fibrotic response [3] . In particular, tranilast is an antifibrotic agent that inhibits several profibrotic growth factors [4] [5] [6] . Recent efforts have been made for the development of tranilast analogs to optimize the antifibrotic effects and reduce toxicity at higher doses [7] . For instance, modification of functional groups on the cinnamoyl ring and the introduction of halogens resulted in cinnamoyl anthranilates with higher bioavailability and enhanced inhibitory effects on fibrosis [8] [9] [10] [11] [12] . Other structure optimizations have included double bond saturation resulting in dihydrocinnamoyl anthranilates such as dihydroavenanthramide D (DHavnD, Fig 1B) , which is an anti-inflammatory used for the treatment of skin disorders and is currently evaluated for its antidiabetic and anticancer effects [13] [14] [15] . Benzoyl anthranilates ( Fig 1C) are found in some plant species such as D. caryophyllus [16] ; and several analogs were shown to inhibit human aldo-keto reductases involved in different pathophysiological conditions such as prostate cancer [17] , as well as to possess cytotoxic activity toward cancer cell lines [18] . Moreover, certain halogenated benzoyl anthranilates are candidates for the treatment of infectious diseases because of their inhibitory effects on the malaria agent Plasmodium falciparum [19] , the human African trypanosomiasis agent Trypanosoma brucei [20, 21] , and the opportunistic pathogenic bacterium Pseudomonas aeruginosa [22, 23] .
The chemical synthesis of pharmaceuticals such as cinnamoyl and benzoyl anthranilatesor their purification from source organisms-consumes nonrenewable petroleum-based chemicals, generates toxic byproducts that require downstream waste-processing, and increases production costs. By contrast, biological synthesis is an eco-friendly production method with reduced requirements for toxic chemicals and natural resources. It offers consistent quality, scalability, simple extraction, and potential for higher synthesis efficiency [24] . In addition, biological synthesis could expand the chemical diversity of natural products, the structural complexity of which is sometimes challenging to achieve using multistep chemical synthesis [25] . In this area, the industrial microorganism yeast (Saccharomyces cerevisiae) has emerged as a powerful tool for the biosynthesis of secondary metabolites considering its advantages for the expression of complex metabolic pathways [26] . We previously reported on a yeast strain engineered for the production of tranilast and several analogs [27] . Cinnamates supplied to this strain are converted into coumaroyl-CoAs by 4-coumaroyl:CoA ligase 5 (4CL5) from Arabidopsis thaliana and coupled to anthranilate or 3-hydroxyanthranilate by hydroxycinnamoyl/benzoyl-CoA:anthranilate N-hydroxycinnamoyl/ benzoyltransferase (HCBT) from D. caryophyllus (Fig 2) . In an earlier study, 13 methoxylated and hydroxylated cinnamates were successfully used as precursors for the production of the corresponding hydroxy/methoxycinnamoyl anthranilates [27] . Here, we show how we extended our yeast production platform by screening several new cinnamate derivatives that could potentially be converted by our yeast strain into cinnamoyl anthranilates and explored benzoates as precursors for the production of benzoyl anthranilates (Fig 2) . First, a series of halogenated cinnamates were tested because of the importance of halogen groups-particularly fluoride-in drug development [28, 29] . Second, several dihydrocinnamates, which correspond to cinnamates with a saturated double bond on the propanoid tail, were tested and successfully converted into dihydrocinnamoyl anthranilates-including those that were halogenated. Third, since HCBT is known to use benzoyl-CoA in addition to coumaroyl-CoA [30] , we attempted to feed the yeast strain with benzoic acid derivatives and confirmed production of a series of halogenated benzoyl anthranilates.
Altogether, our data demonstrate that the substrate promiscuity of both 4CL5 and HCBT can be exploited for biological synthesis of structurally diverse cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates of potential pharmaceutical value.
Materials and Methods

Chemicals
The cinnamates, dihydrocinnamates (or 3-phenylpropionates), and benzoates used for the yeast feeding experiments are listed in S1, S2 and S3 Tables and were purchased from VWR International (Radnor, PA, USA). DHavnD and dianthramide B were obtained from Enamine Ltd (Monmouth Jct., NJ) and Sigma-Aldrich (Saint-Louis, MO), respectively.
Expression of 4CL5 and HCBT in yeast
The pDRf1-4CL5-HCBT1, pDRf1-HCBT1, and pDRf1-4CL5 vectors [27] were used for the expression of At4CL5 (At3g21230, also named At4CL4 in original studies [31] ) and a codonoptimized HCBT (GenBank: Z84385.1) under the control of the constitutive promoters P HXT7 and P PMA1 , respectively. The S. cerevisiae pad1 knockout (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δpad1, ATCC 4005833) [32] was transformed using the Frozen-EZ Yeast Transformation II Kit™ (Zymo Research Corporation, Irvine, CA) and selected on solid medium containing Yeast Nitrogen Base (YNB) without amino acids (Difco 291940; Difco, Detroit, MI) supplemented with 3% glucose and 1X dropout-uracil (CSM-ura; Sunrise Science Products, San Diego, CA). A pad1 knockout was chosen because PAD1 is a known phenylacrylic acid decarboxylase whose deletion in yeast prevents the degradation of exogenously supplied cinnamates [33, 34] .
Production of cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates
An overnight culture from a single colony of the pDRf1-4CL5-HCBT1 recombinant yeast grown on 2X YNB medium without amino acids, supplemented with 6% glucose and 2X CSM-Ura, was used to inoculated 4 mL of fresh minimal medium at an OD 600 = 0.15 and shaken at 200 rpm at 30°C. All precursors were prepared in DMSO and added 5 hours post inoculation at the concentrations indicated in S1, S2 and S3 Tables. The anthranilate acceptors were added to the medium at a final concentration of 300 μM (for anthranilate, 3-hydroxyanthranilate, 3-methylanthranilate, and 5-nitroanthranilate) or 50 μM (for 3-chloroanthranilate, 5-methylanthranilate, 3-methoxyanthranilate, 5-fluoroanthranilate, 5-iodoanthranilate, and 5-chloroanthranilate). These concentrations were selected to limit toxicity and growth inhibition due to either the supplied precursors or the metabolites produced. The cultures were shaken at 200 rpm at 30°C for 24 h in the presence of the precursors for the production of cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates. Yeast colonies harboring the pDRf1-HCBT1 or pDRf1-4CL5 control vectors were grown under similar conditions. For the detection of metabolites, an aliquot of the culture medium was collected and cleared by centrifugation (21,000xg for 5 min at 4°C), mixed with an equal volume of cold methanol:water (1:1, v/v), and filtered using Amicon Ultra centrifugal filters (3,000 Da MW cutoff regenerated cellulose membrane; Millipore, Billerica, MA) prior to LC-TOF MS analysis. The separation and identification of the metabolites were performed using high-performance liquid chromatography (HPLC), electrospray ionization (ESI), and time-of-flight (TOF) mass spectrometry (MS) as previously described [35] . For each compound, the measured masses agreed with the expected theoretical masses within less than 5 ppm mass error. Standard solutions of DHavnD and dianthramide B were prepared in methanol:water (1:1, v/v). Values obtained for the production of DHavnD and dianthramide B are the average of four replicates (n = 4). ESI-MS spectra of other cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates were obtained from single feeding experiments for each combination of precursors.
Results
Production of halogenated cinnamoyl anthranilates
A yeast strain that co-expresses 4CL5 and HCBT was used as a catalyst for the production of non-natural halogenated cinnamoyl anthranilates. We showed previously that HCBT can accept anthranilate or 3-hydroxyanthranilate as substrates for the production of cinnamoyl anthranilates [27] . We further investigated the substrate promiscuity of HCBT and the possibility of producing additional cinnamoyl conjugates by feeding the yeast strain with new anthranilates in combination with p-coumarate. Of 10 anthranilates individually supplied to the culture medium, five novel p-coumaroyl anthranilates were conclusively produced upon feeding with 3-methylanthranilate, 3-methoxyanthranilate, 3-chloroanthranilate, 5-methylanthranilate, and 5-fluoroanthranilate-indicating that HCBT can also accept these anthranilate analogs ( Table 1, S1 Fig) . Based on their expected masses, these compounds were identified by LC-MS analysis of the culture medium but could not be detected in control yeast cultures grown with only anthranilates (without p-coumarate). Next, to assess the capacity of the yeast strain to produce non-natural cinnamoyl anthranilates, we fed the 4CL5-and HCBT-expressing yeast strain several halogenated cinnamates in combination with the seven different anthranilates identified as HCBT acceptors. As a result, 45 novel halogenated cinnamoyl anthranilates were biosynthesized out of 98 combinations tested using a series of 14 fluorinated, chlorinated, and brominated cinnamates ( Table 1, S1 Fig) . These results demonstrate the coenzyme A-ligase activity of 4CL5 toward these non-natural cinnamates and the capacity of HCBT to couple the corresponding CoA-thioesters to various anthranilates.
Production of dihydrocinnamoyl anthranilates
We attempted to produce dihydrocinnamoyl anthranilates by feeding the yeast strain with various dihydrocinnamates (i.e., 3-phenylpropionate derivatives) and anthranilates. First, by comparison with the LC-MS elution profile of an authentic standard, the production of DHavnD (4.03 ± 0.08 μM) was successfully achieved by feeding 4-hydroxydihydrocinnamate and anthranilate (Fig 3) , which indicated the promiscuity of 4CL5 and HCBT to use as substrates the saturated propanoid tail of cinnamate and cinnamoyl-CoA, respectively. No DHavnD was detected from the culture medium of control strains, fed with the same precursors and expressing either 4CL5 or HCBT alone. Next, as a preliminary round of screening, the medium of the engineered yeast was supplied with a series of 22 dihydrocinnamates (including halogenated dihydrocinnamates) in combination with anthranilate, which led to the production of 14 individual dihydrocinnamoyl anthranilates, according to the LC-MS analysis of the medium ( Table 2, S2 Fig) . The dihydrocinnamates that yielded a detectable product in the first round of screening were then co-fed with 3-hydroxyanthranilate or 3-methylanthranilate, which resulted in the production of 13 additional dihydrocinnamoyl anthranilates ( Table 2, anthranilates, demonstrating again the substrate promiscuity of both 4CL5 and HCBT enzymes in our in vivo production system.
Production of benzoyl anthranilates
The production of benzoyl anthranilates by the 4CL5-HCBT yeast strain was tested because of the capacity of HCBT to use benzoyl-CoA as a donor in addition to coumaroyl-CoA [30] . We first successfully produced a benzoyl anthranilate named dianthramide B (1.20 ± 0.12 μM), by feeding the 4CL5-and HCBT-expressing yeast strain with benzoic acid and anthranilate. The identity of this new compound, which was detected directly from the culture medium, was confirmed with the authentic standard that exhibits the same LC-MS elution profile and mass (Fig  4) , and by its absence in control cultures of strains expressing either 4CL5 or HCBT alone. Considering this unexpected substrate affinity of 4CL5 for benzoic acid, we fed 75 benzoate derivatives in combination with anthranilate for the synthesis of the corresponding benzoyl conjugates. This preliminary screening resulted in the production of 34 individual benzoyl anthranilates, including halogenated benzyol anthranilates, which were detected directly from the culture medium by LC-MS analysis (Table 3, S3 Fig) . A second round of production using 3-hydroxyanthranilate or 3-methylanthranilate instead of anthranilate in the culture medium led to the production of 50 additional benzoyl anthranilates ( 
Discussion
With an emphasis on the class of cinnamyol, dihydrocinnamoyl, and benzoyl anthranilates, we illustrate in this study the possibility of producing numerous chemically diverse molecules using biological synthesis rather than conventional chemical synthesis. Our data imply that the promiscuity of 4CL5 allows the catalytic conversion of a great diversity of dihydrocinnamates, benzoates, and various cinnamates into the corresponding acyl-CoA-thioesters. To our doi:10.1371/journal.pone.0138972.g004 Table 3 . Structural characteristics of the benzoyl anthranilates (general structure shown in Fig 1C) [36, 37] . Nevertheless, using the 4CL5 enzyme, we demonstrate the feasibility of producing a substantial diversity of benzoyl-CoA thioesters and benzoate conjugate molecules in yeast. This discovery opens new possibilities for the heterologous combinatorial production of valuable benzoylated metabolites such as benzylbenzoates; benzophenones; the anticancer drug taxol; polyketides with antimicrobial activities (e.g., wailupemycin, enterocin, soraphen A); and unnatural polyketides using engineered benzoyl-CoAdependent polyketide synthases [38] . Furthermore, heterologously synthesized benzoyl anthranilates can be used as scaffolds for the synthesis of related anti-adenoviral compounds and oncogene inhibitors [39, 40] . We observed the activity of 4CL5 towards various dihydrocinnamates and non-natural halogenated cinnamates and exploited its catalytic property to biosynthesize libraries of nonnatural and structurally diverse cinnamoyl and dihydrocinnamoyl anthranilates using HCBT. For example, the drug DHavnD was synthesized, and utilization of alternate precursors resulted in the rapid production of 27 additional DHavnD analogs. These results point towards the eventual design of more biologically active drugs through the addition of halogens. They also illustrate the advantage of biological synthesis to achieve bifunctionalization, as exemplified by several of our bi-halogenated compounds. Finally, through co-expression with the adequate synthases, the capacity of 4CL5 to activate dihydrocinnamates creates the potential for biomanufacture of valuable natural products, such as the antibacterial dihydrocinnamoyl forms of flavans and chalcones [41, 42] .
The HCBT enzyme used in this study belongs to the BAHD enzyme family, which contains multiple members that catalyze the transfer of cinnamoyl-and benzoyl-CoAs into a great diversity of distinct acceptors [43] . Although HCBT offers flexibility for a wide range of acylCoA donors, its affinity towards acceptors seems limited to anthranilates. Therefore, engineering yeast strains that co-express 4CL5 with various BAHD transferases would considerably expand the type and number of molecules that can be biosynthesized heterologously.
Ultimately, biosynthesis of particular cinnamoyl or benzoyl anthranilates from renewable and inexpensive carbon sources could be desirable for cost-effective manufacturing. For this purpose, we recently demonstrated a de novo pathway for the production of p-coumarate and two avenanthramides from glucose in E. coli [35] . In this pathway, additional expression of hydroxycinnamoyl-CoA double-bond reductase could be used for the synthesis of dihydrocinnamates [44] , whereas benzoate biosynthesis can be achieved from the aromatic amino acid phenylalanine [45] . Finally, the recent discovery of halogenases from bacteria and fungi has already proven to be useful for de novo synthesis of halogenated bioactive metabolites in microorganisms [46, 47] .
As a conclusion, the use of two promiscuous enzymes, 4CL5 and HCBT, demonstrates the potential to develop a platform for the precursor-directed combinatorial biosynthesis of cinnamoyl, dihydrocinnamoyl, and benzoyl anthranilates. In this study and in our previous work [27] , this system using a single engineered yeast strain supported the production of more than 180 target metabolites belonging to cinnamoyl, dihydrocinnamoyl, or benzoyl anthranilate families. Moreover, we believe that testing our system with more substituted cinnamates and benzoates could result in the production of several additional metabolites. Table 3 . (PPTX) S1 
